

## PRESS RELEASE

### RescueFlow® improves survival in early sepsis

Results from two independent studies where **RescueFlow®** (7.5% sodium chloride, 6% dextran 70) has been used for septic shock, have recently been presented by two Swedish research groups.

“The findings of these studies from respected research institutes are a major step forward in our program for the further development of **RescueFlow®** and confirm those from previous studies on RescueFlow®,” says Soili Longsén, Managing Director of BioPhausia.

During the *European Society for Intensive Care Medicine* congress in Rome, early October 2000, the Huddinge University Hospital, Karolinska Institute, and the Defence Research Establishment (FOA), Stockholm, presented an experimental study where RescueFlow® was used in septic shock. All animals in the RescueFlow® group survived, whereas only 3 out of 8 animals survived in the control group.

The Sahlgrenska University Hospital, Gothenburg (Oi *et al*) recently reported similar findings regarding survival.

The conclusions from both studies are that volume resuscitation with HSD demonstrates beneficial effects in terms of survival in an early phase of septic shock. This is probably due to a better maintenance of central and regional circulation and thereby an improved vital organ perfusion with better oxygenation and urine production.

Uppsala Sweden 19 october 2000

For more information please contact :

Soili Longsén, Managing Director, BioPhausia AB tel +46-(0)18 - 34 99 00 or mobile +46- (0)708-32 92 19

Claes Thulin, Chairman of the Board, BioPhausia AB tel +46-(0)708 - 99 34 50